From its introduction, oncological chemotherapy has been
encumbered by its poor selectivity because most antiproliferative
drugs are toxic not only to tumor cells but also to important
populations of the body s non-neoplastic cells. The resultant
problems with unwanted side effects are compounded by difficulties
in predicting the desired effectivity of chemotherapy in individual
patients.
This unsatisfactory situation has driven intensive research and
development towards more specific and less toxic anticancer drugs
over the last few decades. Several results of these efforts have
reached the clinic and an even greater number are now in
preclinical testing.
Common to all these targeted therapies is their interaction with
defined molecules present on cancer cells, which adds various
degrees of increased selectivity to their toxic effects. As a
consequence, detecting the target molecule on tumors before therapy
holds great diagnostic potential for predicting the efficacy of the
drug and personalizing therapy.
This book aims to present translational scientists and
clinicians with an integrated critical view on the theories,
mechanisms, problems and pitfalls of the targeted therapy
approach."
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!